click below
click below
Normal Size Small Size show me how
WEEK 19:
Pharmacogenetics:
| Question | Answer |
|---|---|
| pharmacogenetics | genetic variations in that lead to changes in pharmacokinetics and pharmacodynamics of drugs between individuals across populations |
| why do patients fail to respond to treatment/ have adverse effect (2) | metabolism (renal function, drug-drug interactions, and resistance) and pharmacogenetics (ethnicity), |
| polymorphisms | ability to take many forms eg SNP (single nucleotide polymorphism) leading to mutation and amino acid substitution |
| example of SNP (single nucleotide polymorphism) | sickle cell anaemia |
| P450 cytochromes | make up a lot of enzymes involved in metabolism |
| CYP2D6 means | cytochrome P450, family 2, subfamily D, polypeptide 6 |
| classes of metabolisers | poor (not metabolised), intermediate, extensive, and ultra-rapid |
| what does the class of metabolisers (eg poor) depend on | variation of CYP2D6 |
| warfarin | oral anticoagulant metabolised by CYP2C9 polymorphism- acts a vitamin K antagonist where S-enantiomer reduces clearance so lower dose required |
| s warfarin mechanisms | inhibits VKOR (VKOR converts vitamin K into y-glutamyl carboxylase which activates blood clotting factors) |
| vitamin K epoxide reductase complex 1 (VKORC1) | gene encoding subunit 1 of VKOR |
| what happens when S warfarin is metabolised by CYP2C9 | inactivates metabolites which reduces warfarin being broken down which decreases warfarin activity (more left in blood) so dose needs to be decreased |
| warfarin therapeutic window | narrow |
| vitamin K rich foods do what | reduce effectiveness of warfarin |
| aspirin resistance | 1/4 patients are resistance and it is not related to COX- can lead to increased risk of CVD as it is an anti-platelet |
| clopidogrel | anti-platelet and pro drug (inactive form) and first line treatment to overcome aspirin side effects |
| major determinant of clopidogrel efficacy | paraoxonase-1 (PON1) |
| what happens to clopidogrel when it is metabolised by PON1 Q192R | increases risk of thrombosis on stent |
| codeine -> morphine transformation | catalysed by CYP2D6, giving it analgesia (inability to feel) and CNS-depressant effects |
| haplotypes | combination of alleles/ set of SNPs found on same chromosome eg different haplotypes means different warfarin requirements |
| rosuvastatin prevalence and dose varies depending on | racial groups |